TGFB1 and Hepatic fibrosis: In rats with type-2 diabetes, Qiang et al. demonstrated that valsartan could block the pathological course of liver fibrosis by down-regulating the expression of α-smooth muscle actin, TGF-β1, TNF-α, and MCP-1, and anti-apoptosis to restore the injured hepatic mitochondrial respiratory function [108].